WO2017111529A1 - Ovulation and implantation herbal medicine extract having implantation enhancing effect, and use of same - Google Patents

Abstract

The present invention relates to an ovulation and implantation herbal medicine extract having an implantation enhancing effect and to a use of the same and, more particularly, to a composition for preventing, alleviating, or treating infertility caused by an implantation disorder, the composition comprising an ovulation and implantation herbal medicine extract as an active ingredient. The ovulation and implantation herbal medicine extract according to the present invention has low side effects and can help to maintain pregnancy by enhancing not only ovulation but also the implantation of a fertilized egg, and thus the ovulation and implantation herbal medicine extract can be used as a medical product and a health functional food which are useful in alleviating, preventing, controlling, or treating infertility and sterility caused by an implantation disorder. In addition, the ovulation and implantation herbal medicine extract according to the present invention not only has an antioxidant function but also exhibits an excellent effect of protecting against generative cell toxicity caused by VCD which is a representative ovary toxic material, and thus the ovulation and implantation herbal medicine extract can be used as a medical product and a health functional food which are useful in alleviating, preventing, controlling, or treating premature ovarian failure and perimenopause.

Description

Ovulation releasing extract having implantation promoting effect and use thereof

The present invention relates to an ovulation implantation extract and its use having an implantation promoting effect, and more particularly to a composition for the prevention, improvement or treatment of infertility due to implantation disorders comprising an ovulation implantation extract as an active ingredient.

In recent years, with the aging society, infertility is increasing as the age of mothers giving birth increases. In addition, as the stress on women increases due to environmental pollution due to industrialization and social advancement of women, the pregnancy rate is greatly reduced. Male and female cavities include genetic defects, environmental defects, and endocrine disorders. Male causes include sperm and semen defects. Ovulation disorders, transfer disorders and implantation disorders of the fertilized egg.

To solve this infertility, various infertility procedures and assisted reproductive technology are being developed. Currently, the most commonly used procedures are intrauterine insemination (IU) and in vitro fertilization-embryo transfer. , IVF-ET, in vitro fertilization). Although these procedures have different application points, there are disadvantages such as complicated procedures, overcomplications caused by ovulation, low pregnancy success rate of about 10-30%, and mental and financial pain of the family due to the procedure failure. . In addition, the current medical technology is inconvenient to treat infertility due to implantation disorders, many bar, there is a demand for the development of infertility treatments that can increase the efficiency of implantation.

As described above, research on the development of a therapeutic agent that can treat infertility by improving implantation efficiency has been of major interest, and research on this is ongoing (Korea Patent Publication No. 10-2010-0049153), but it is still inadequate. to be.

The present invention has been made to solve the above-mentioned problems in the prior art, the inventors of the present invention while studying on the natural resources excellent in inducing the effect of implantation of fertilized eggs, ovarian complexion is a mixed extract of 11 medicinal herbs side effects It was confirmed that the effect of promoting the implantation of the fertilized egg is small, and the present invention was completed based on this.

Accordingly, an object of the present invention is to provide a pharmaceutical composition or health functional food composition for the prevention, improvement or treatment of infertility due to implantation disorders, including the ovulation releasing extract as an active ingredient.

Another object of the present invention is to provide a pharmaceutical composition or health functional food composition for the prevention, improvement or treatment of ovarian toxicity and premature ovarian failure, comprising the ovulation upper release extract as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of infertility due to implantation disorders, including the ovulation releasing extract as an active ingredient.

In one embodiment of the present invention, the ovulation complex uptake extract may comprise earth and sand, bokbunja, ginseng, wolfberry, Angelica, berry, sine, leafy, acid, ginger and jujube.

In another embodiment of the present invention, the earth and sand, bokbunja, ginseng, wolfberry, Angelica, jasminoides, signatures, leaflets, powder, ginger and jujube 10-15%: 10-20%: 4-9%: 4-9 %: 1 ~ 5%: 4 ~ 9%: 4 ~ 9%: 4 ~ 9%: 20 ~ 30%: 2 ~ 7%: 1 ~ 5%

In another aspect, the present invention provides a dietary supplement for the improvement of infertility due to implantation disorders, including the ovulation upset extract as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for preventing or treating egg toxicity, comprising as an active ingredient ovulation upper compartment extract.

In another aspect, the present invention provides a pharmaceutical composition for preventing or treating premature ovarian failure, comprising the ovulation upper release extract as an active ingredient.

The present invention also provides a method for the prevention or treatment of infertility, egg toxicity or premature ovarian failure due to implantation disorders comprising administering to the subject ovulation extract.

The present invention also provides a prophylactic or therapeutic use of infertility, egg toxicity or premature ovarian failure due to implantation disorders of ovulation releasing extract.

Ovulation releasing extract according to the present invention has fewer side effects, and can help to maintain pregnancy by promoting not only ovulation but also fertilization of fertilized egg, useful for improving, preventing, suppressing or treating infertility, infertility due to implantation disorders, etc. It can be used as medicine and dietary supplement.

Furthermore, the ovulation releasing extract according to the present invention not only has an antioxidant action but also shows an excellent protective effect on germ cell toxicity by VCD, which is a representative ovarian toxic substance, improving, preventing, such as premature ovarian failure and premenopausal disorders. It can also be used as a pharmaceutical and nutraceutical that is useful for inhibition or treatment.

Figure 1 compares the results of pregnancy success rate between the group fed the normal feed (normal group) and the group fed the feed containing a low concentration of ovulation upper and the group fed a feed containing a high concentration of ovulation.

FIG. 2 compares the number of pups born between the group fed the normal feed and the group fed the feed containing the low concentration of ovulation and the group fed the feed containing the high concentration of ovulation.

Figure 3 shows the total weight change of the group fed the feed containing the normal feed (normal group) and the feed containing the low concentration ovulation upper and the feed containing the high concentration ovulation upper.

Figure 4 shows the total feed intake of the group fed the feed containing the normal feed (normal group) and the feed containing the low concentration ovulation upper, the feed containing the high concentration ovulation upper.

Figure 5 shows the food efficiency ratio (Food efficiency ratio) of the group fed a feed containing a normal feed (normal group) and a feed containing a low concentration ovulation upper and a feed containing a high concentration ovulation upper.

Figure 6 is a photograph taken from the uterus to confirm the embryo implantation of the normal group, RU486 treatment group and ovulation implantation high concentration intake + RU486 treatment group.

Figure 7 shows the results of counting the number of fetuses in the normal group, RU486 treatment group and ovulation high concentration intake + RU486 treatment group.

Figure 8 is the result of measuring the DPPH radical and Superoxide anion radical scavenging activity of the ovulation uptake extract.

Figure 9 is the result of measuring the antioxidant activity of the cells of the ovulation upstream extract through the H ₂ DCF-DA test method.

Figure 10 is a result confirming the protective effect of the ovulation uptake extract against ovotoxicity induced by VCD.

Figure 11 shows the results of confirming the cytotoxicity of the ovulation upstream extract alone against CHO-K1 cells.

The present invention provides a pharmaceutical composition for the prevention or treatment of infertility due to implantation disorders, including the ovulation releasing extract as an active ingredient.

In the present invention, the "ovulation releasing extract" means the extract extracted from 11 medicinal herbs, the 11 medicinal herbs are earth and sand, bokbunja, ginseng, wolfberry, Angelica, leaflet, coriander, leaf lobe, mountain medicine, ginger and jujube It is to include.

In the composition of the present invention, the earth and sand, bokbunja, ginseng, wolfberry, donkey, jasminoide, coriander, larvae, powder, ginger, and jujube 10-15%: 10-20%: 4-9%: 4-9%: 1 to 5%: 4 to 9%: 4 to 9%: 4 to 9%: 20 to 30%: 2 to 7%: 1 to 5% by weight ratio, and more preferably 11 to 14% : 14 ~ 18%: 5 ~ 7%: 5 ~ 7%: 2 ~ 4%: 5 ~ 7%: 5 ~ 7%: 5 ~ 7%: 23 ~ 28%: 3 ~ 6%: 2 ~ 4% It can be combined in a weight ratio of.

Ovulation complex upper extract as an active ingredient in the composition of the present invention can be obtained by a conventional extraction method, can be purchased commercially available. Conventional extraction methods may include, but are not limited to, hot water extraction, cold needle extraction, reflux extraction, ultrasonic extraction, and the like.

In the present invention, the ovulation releasing extract can be obtained by the following method. First, earth and sand, bokbunja, ginseng, wolfberry, Angelica, jasminoides, coriander, larvae, powder, ginger, and jujube are thoroughly washed with water, dried, mixed and ground. The pulverized mixture is extracted under reflux for 1 to 5 hours, preferably 1 hour and 30 minutes at 50 to 100 ° C. with water, a C ₁ to C ₄ alcohol or a mixed solvent of water and C ₁ to C ₄ alcohols. At this time, the volume of the solvent is 1 to 10 times, preferably 5 to 8 times the weight of the pulverized mixed medicine. Thereafter, the extract is filtered, the filtrate is concentrated, and the concentrate is lyophilized to obtain an ovulation upper extract in the form of a powder.

Implantation is an early stage of pregnancy in which the fertilized blastocyst, which develops as an embryo, attaches to the endometrial layer of the mother, and is a normal pregnancy (natural pregnancy), in particular, a successful fertilization in artificial insemination and in vitro procedures. Even if this is done, fertilization of fertilized embryos in the mother's endometrium may be successful to increase pregnancy rate. Therefore, the present inventors confirmed the effect of ovulation upper extract to enhance the conception of such fertilized eggs as well as ovulation.

In one embodiment of the present invention, as a result of comparing the gestation success rate and the number of pups born in each group to the group fed the feed containing the low concentration / high concentration ovary fry up, and not the other group, fed the feed containing ovulation upper In addition to the high pregnancy success rate, more pups were given birth, and even when the pill (RU486) was treated, the group containing the high concentration of ovulation was found to have higher embryo implantation rate than the pill (RU486) treated group. (See Example 2).

In another embodiment of the present invention, as a result of confirming the antioxidant efficacy of the ovulation uptake extract, it was confirmed that exhibits excellent DPPH radical and Superoxide anion radical scavenging activity and intracellular antioxidant capacity, and the cytoprotective effect from ovarian toxicity induced by VCD It was confirmed that there was (see Examples 3 to 5).

Therefore, the ovulation implantation extract according to the present invention has fewer side effects and can help to maintain pregnancy by promoting implantation of fertilized eggs, drugs useful for improving, preventing, suppressing or treating infertility, infertility, etc. due to implantation disorders. And as a dietary supplement.

In addition, the ovulation uptake extract of the present invention not only has an antioxidant action but also shows an excellent protective effect on germ cell toxicity by VCD (4-vinylcyclohexene diepoxide), which is a representative ovarian toxic substance, premature ovarian failure, premenopausal disorders It can also be used as medicines and health functional foods useful for improving, preventing, suppressing or treating the back.

Thus, as another aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of egg toxicity or premature ovarian failure, comprising the ovulation releasing extract as an active ingredient.

The pharmaceutical composition of the present invention may further contain at least one known active ingredient having a therapeutic effect of infertility, infertility or premature ovarian insufficiency together with ovulation releasing extract.

The composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions. It may also be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions according to conventional methods.

Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose , Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. In formulating the composition, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.

The pharmaceutical compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts. The pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight of the patient, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the type of disease, the drug used in general May be administered 0.0001 to 150 mg, preferably 0.001 to 100 mg daily or every other day or divided into 1 to 3 times a day per kg body weight. However, the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.

In addition, as another aspect of the present invention, the present invention provides a health functional food composition for improving infertility or premature ovarian failure due to implantation disorders comprising an ovulation upper chamber extract as an active ingredient.

As used herein, the term "improvement" refers to any action that at least reduces the parameters associated with the condition being treated, such as the extent of symptoms.

The composition of the present invention may be added to a dietary supplement for the purpose of preventing or improving infertility or premature ovarian failure due to implantation disorders. When using the ovulation releasing extract of the present invention as a food additive, the ovulation releasing extract can be added as it is or used with other foods or food ingredients, and can be suitably used according to a conventional method. The mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the preparation of food or beverage, the ovulation upper extract of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less based on the raw material. However, in the case of long-term intake for health and hygiene or for health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and includes all of the dietary supplements in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. Natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The proportion of the natural carbohydrate is generally about 0.01-0.20 g, preferably about 0.04-0.10 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.

In still another aspect of the present invention, the present invention provides a method for preventing or treating infertility, premature ovarian failure, or premenopausal menopausal disorder due to an implantation disorder comprising administering to the subject an ovulation releasing extract. The subject is a human or non-human mammal, and non-human mammals include, but are not limited to, mice, rats, dogs, cats, horses, cattle, sheep, goats, pigs, rabbits, and the like.

Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the following examples.

EXAMPLE

Example  One. Ovulation  Extract manufacturer

Earthenware: Bokbunja: Ginseng: Wolfberry: Angelica: Azalea: Sine: Leafy leaf: Powder: Ginger: Jujube 8:10: 4: 4: 2: 4: 4: 4: 16: 3: 2 Ovulation The cultured eggplant (240 g) was bathed in 1 L of tertiary distilled water for 1 hour 30 minutes, the extract was centrifuged and filtered, frozen at -80 ° C, and lyophilized. Lyophilized herbs were weighed and stored at -80 ° C.

Example  2. Ovulation  Verification of Efficacy in Infertility by Enhancement of Extraction

2-1. Confirmation of Treatment Efficacy in Animal Models According to Ovulation Extracts

In order to confirm that the ovulation grafting extract prepared in Example 1 is effective in the treatment of infertility through implantation enhancement, 5-week-old male and 4-week-old female Balb / c were purchased and used in the experiment after 1 week of adaptation. It was assumed that the amount of feed that one mouse consumes per day was 5 g, and the medicinal feed was prepared by mixing the feed with intake concentrations of ovulation upper body at 100 mg / kg (low concentration) and 300 mg / kg (high concentration). The group fed the normal diet (normal group), the group fed the feed containing the low concentration ovulation upper (low ovulation upper concentration: 100mg / kg / day), the group fed the feed containing the high concentration ovulation upper (high ovulation high concentration) : 300mg / kg / day), each group consisted of 4 males and 8 females, and each group was fed with feed containing the drug for 1 week, then 1 6-week-old male and 5 per cage. Two week-old females were put together for 5 days, and when vaginal plugs were seen, it was regarded as the first day of pregnancy. After that, the pregnancy success rate and the number of cubs born were compared.

As a result, as shown in Figs. 1 and 2, in the normal group, low concentration and high concentration of ovulation, 6 of 8 pregnant / giving birth showed a success rate of 75.0%. In addition, the normal group gave birth to a total of 23 pups from 6 mothers, which gave birth to an average of 3.83 pups, and in the group fed ovulation low concentration (100mg / kg), a total of 23 pups from 6 mothers. After giving birth, an average of 3.83 pups were given as in the normal group. However, the group fed ovulation high concentration (300mg / kg) gave birth to a total of 37 from 6 mothers, giving birth to an average of 6.17 pups. , Significant difference was shown (p <0.05).

2-2. Body weight, feed intake and feed intake evaluation

Total weight change, total feed intake, and feed intake efficiency of the normal and ovulation uptake groups were evaluated during the 35-day experimental period.

As a result, as shown in Figures 3 to 5, there was no significant difference in the total weight change, feed intake and feed intake efficiency between the normal group and ovulation uptake group.

From the above results, it was confirmed that the intake of the ovulation uptake extract according to the present invention does not affect the dietary efficiency in the animal model.

2-3. Confirmation of Efficacy of Embryonic Implantation Failure in Animal Model According to Ovulation Occurrence Extract

In order to determine whether the ovulation locust extract prepared in Example 1 affects implantation even when the contraceptive pill (RU486) treatment, 5-week-old male and 4-week-old female Balb / c as in Example 2-2 Was purchased and used for the experiment after one week of adaptation. Thereafter, the experimental group was fed the normal diet (normal group), the group injected with subcutaneous injection of 0.08 mg / 0.1 ml of RU486 (RU486 treatment group) on the fourth day of pregnancy, and the group fed the diet containing high concentration of ovulation. On the day, subcutaneous injection of 0.08mg / 0.1ml of RU486 (ovulation high concentration intake + RU486 treatment group) was performed, and each group was fed with one 6-week-old male and two 5-week-old females per cage. When the vaginal plug was seen, it was regarded as the first day of pregnancy. RU486 treatment group and ovulation implantation high concentration intake + RU486 treatment group was administered subcutaneous injection of RU486 on the fourth day of pregnancy, and one week after RU486 injection, the number of implanted embryos was examined.

As a result, as shown in FIGS. 6 and 7, 20 embryos were implanted in 3 mothers in the normal group, and an average of 6.67 embryos were implanted, whereas in the RU486-treated group, 5 embryos were implanted. A total of 5 embryos were implanted, and an average of 1 embryos were implanted, indicating a significant decrease (p <0.01). However, in the ovulation high concentration intake + RU486 treatment group, a total of 19 embryos were implanted from 6 mothers and an average of 3.17 embryos were implanted, indicating that there was no significant difference from the normal group ( p = 0172).

From the above results, the number of embryos implanted was lower than that of the normal group, but it was confirmed that RU486 was higher in the ovulation-implantation high concentration intake + RU486 treatment group than the treatment group. This confirmed that even after treatment with contraceptive pill (RU 486), ovulation implantation could further induce the fertilization of rat embryos.

Example  3. Ovulation  Antioxidant Activity of Extracts

DPPH radical scavenging activity was measured to confirm the antioxidant efficacy of the ovulation complex. More specifically, first, 1 ml of 1M DPPH solution and 450 µl of 50 mM Tris-HCl buffer (pH 7.4) were added and mixed to 50 µl of the ovulation upper extract. The mixture was allowed to react at room temperature for 30 minutes, and then absorbance was measured at a wavelength of 517 nm using a microplate reader (VersaMax, Molecular Devices, USA).

In addition, the scavenging activity for the peroxide anion, which is one of the representative active oxygen species as another indicator of the antioxidant activity, was measured using the NBT reduction method. More specifically, 10 μl of 30 mM EDTA (pH 7.4), 1 μl of 30 mM hypoxanthine, and 200 μl of 1.42 mM NBT were added to 30 μl of the sample, followed by 3 minutes of reaction at room temperature. Then, 10 μl of 1U / ml xanthine oxidase was added and 50 mM phosphate was added. The total volume was adjusted to 300 μl with buffer (pH 7.4), and the reaction solution was incubated at room temperature for 20 minutes, and then absorbance was measured at 560 nm.

As a result, as shown in Figure 8, it was confirmed that the ovulation upper extract has an excellent antioxidant effect, in particular, the higher the concentration was confirmed that the antioxidant effect is good.

Example  4. CHO -Induced hydrogen peroxide in K1 cells ROS  About Ovulation  Efficacy Verification

To determine the effect of ovulation uptake on the production of reactive oxygen species (ROS) in CHO-K1 cells under oxidative stress induced by hydrogen peroxide (H ₂ O _{2 )} , the H ₂ DCF-DA test method was used. Intracellular antioxidant activity was measured.

As a result, as shown in Fig. 9, it was confirmed that the ovulation upstream extract shows excellent intracellular antioxidant capacity.

Example  5. CHO VCD-induced in K1 cells Intoxication  ( ovotoxicity For) Ovulation  Validation of Cytoprotective Effect of Extracts

In order to confirm the cytoprotective efficacy of the ovulation releasing extract according to the present invention, cell viability was evaluated by the 3- (4,5-dimethylthiazol) -2,5-diphenyltetrazolium bromide (MTT) assay method.

More specifically, 1 × 10 cells / well of CHO-K1 cells incubated in 96well plate, serum starvation (serum starvation) for 4 hours, after the ovulation uptake to 100㎛ / ㎖, and the VCD (1.5mM) Sequential treatment was incubated for 24 hours at 37 ℃, 5% CO ₂ conditions. Thereafter, 37 ℃ by the addition of MTT solution (2mg / ㎖) of 10㎕ per well, then reacted for 3 hours at 5% CO ₂ incubator, after completely removing the culture medium and MTT solution, of dimethyl sulfoxide 100㎕ (DMSO , Sigma-Aldrich, USA) was dissolved in formazan crystals formed in the cells and the absorbance was measured at 595nm with ELISA plate reader (DYNEX, Opsys MR, USA). At this time, the cell viability of the control group was expressed as a percentage. In addition, the cytotoxicity of the ovulation uptake extract alone was evaluated by MTT assay.

As a result, as shown in Figures 10 and 11, it was confirmed that the ovulation upper extract was excellent in cell protection from the cytotoxicity induced by VCD, CHO-K1 up to 500㎍ / ㎖ when the ovulation upper extract alone treatment Since it does not affect the cell viability, it was confirmed that there is no cytotoxicity.

The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.

Ovulation releasing extract according to the present invention has fewer side effects, and can help to maintain pregnancy by promoting not only ovulation but also fertilization of fertilized egg, useful for improving, preventing, suppressing or treating infertility, infertility due to implantation disorders, etc. It can be used as medicine and dietary supplement.

Furthermore, the ovulation releasing extract according to the present invention not only has an antioxidant action but also shows an excellent protective effect on germ cell toxicity by VCD, which is a representative ovarian toxic substance, improving, preventing, such as premature ovarian failure and premenopausal disorders. It can also be used as a pharmaceutical and nutraceutical that is useful for inhibition or treatment.

Claims (8)

1. A pharmaceutical composition for the prevention or treatment of infertility due to implantation disorders, comprising an ovulation upper chamber extract as an active ingredient.
2. The pharmaceutical composition of claim 1, wherein the ovulation releasing extract comprises earth and sand, bokbunja, ginseng, goji berry, Angelica, cotyledon, coriander, leaf, leaf, ginger, and jujube.
3. The method according to claim 2, wherein the earth and sand, bokbunja, ginseng, goji berry, Angelica, self-leafing, sine, leafy, powdered, ginger and jujube 10-15%: 10-20%: 4-9%: 4-9%: 1 to 5%: 4 to 9%: 4 to 9%: 4 to 9%: 20 to 30%: 2 to 7%: a pharmaceutical composition, characterized in that blended in a weight ratio of 1 to 5%.
4. Health functional food composition for the improvement of infertility due to implantation disorders, including the ovulation upper chamber extract as an active ingredient.
5. Ovulation complex upstairs extract as an active ingredient, preventing or treating pharmaceutical composition for egg toxicity.
6. A pharmaceutical composition for preventing or treating premature ovarian failure, comprising an ovulation upper extract as an active ingredient.
7. A method for preventing or treating infertility, egg toxicity or premature ovarian failure due to an implantation disorder comprising administering to the subject an ovulation extract.
8. Use for the prevention or treatment of infertility, egg toxicity or premature ovarian failure due to implantation disorders of ovulation upper extract.

Images